CD99 and acute lymphoblastic leukemia: Again, in T-ALL, the coverage rate was 100% and all patients (14/14) had 2 LAIPs for follow-up (CD99/CD7/CD3/CD5 and CD7/sCD3/cyCD3/TdT).